This article is only available in the PDF format. Download the PDF to view the article, as well as its associated figures and tables.
NEW HEART is the literal meaning of Novacor, and a group at Stanford (Calif) University School of Medicine that has been using this firm's left ventricular assist system in patients for 6 years believes the device is now ready to fully live up to its name.
A spokesperson for the Novacor Corporation, Oakland, Calif (part of the Baxter Health Care Corporation), says the initial phase of the planned trial of the implantable device will be under the auspices of the National Heart, Lung, and Blood Institute, Bethesda, Md. Site selection is now under way, and it is hoped the trial will start early in 1991.
At the American Association for Thoracic Surgery meeting in Toronto, Canada, Patrick M. McCarthy, MD (who participated in the study as a surgical fellow at Stanford and who is now a cardiac surgeon at the Cleveland Clinic in Ohio), agreed that clinical trials of the
Goldsmith MF. Fully Implanted Left Ventricular Assist Device May Enter Clinical Trials Early in 1991. JAMA. 1990;263(22):2990–2991. doi:10.1001/jama.1990.03440220012003